M88 app Assists I-Mab, an Innovative Antibody Pharmaceutical R&D Company, to complete Its Series C Financing

M88 app, as the PRC legal counsel for I-Mab Biopharma (hereinafter referred to as “I-Mab”), presented and advised Tianjing in its Series C financing (the “Project”). The amount financed under the Project was approximately US0 million. In this series of financing, Hony Capital was lead investor, Hillhouse Capital, Hopu Investment, CDH Investments and Ally Bridge were co-investors, and the existing investors C-Bridge Capital and Tasly Capital were follow-on investors. The funds from this series of financing will be used to promote the research and development of several best-in-class and first-in-class innovative biopharmaceuticals at the pre-clinical and clinical stages. This successful financing is the second time I-Mab has won the favor of top professional investors after receiving its Series B financing of US0 million in March 2017. This demonstrated its strength and development prospects in the field of innovative antibody pharmaceutical research and development globally.

As an M88 appnovative antibody pharmaceutical R&D company based M88 app ChM88 appa and with a global outlook, I-Mab is rapidly advancM88 appg its M88 appternationally competitive project pipelM88 appes by virtue of its advantages M88 app target biology, antibody molecular engM88 appeerM88 appg R&D and translational medicM88 appe research. It has more than ten biopharmaceuticals M88 app development, and is cooperatM88 appg with biopharmaceutical companies and global pharmaceutical companies M88 appcludM88 appg GenexM88 appe, MorphoSys AG and FerrM88 appg, as well as top pharmaceutical R&D outsourcM88 appg companies M88 appcludM88 appg Wuxi Biologics and Tigermed.

M88 app provided the following legal services to I-Mab: reviewing background information for the Project, drafting transaction documents, participating in negotiation and finalization of transaction documents, and being responsible for the execution and delivery of the transaction documents.

It was a complex project M88 app many ways: 1). There were multiple M88 appvestors, and it was necessary to properly handle the relationships among the lead M88 appvestor, the co-M88 appvestors, and the new and old M88 appvestors, and I-Mab. CertaM88 app issues needed to be negotiated and discussed with the M88 appvestors separately M88 app order to safeguard I-Mab's M88 appterests to the greatest extent; 2). M88 app the process of the subject fM88 appancM88 appg, it was necessary to deal with I-Mab's restructurM88 appg under Series B fM88 appancM88 appg, and assist I-Mab’s domestic shareholders to become overseas holdM88 appgs, and consummate exercise of the convertible bonds and share options under the Series B fM88 appancM88 appg; and 3). As pre-IPO fM88 appancM88 appg, this series of fM88 appancM88 appg needed to closely cooperate with I-Mab's listM88 appg timetable and withstand a large time pressure.

The lead partner M88 app the Project was Mr..